Late Recurrence in ER- Positive Breast Cancer: Banking on Biomarkers

Update: 2018-01-17

Description

Evaluation of biomarkers after 5 years of standard therapy for hormone-positive breast cancer may help determine those at risk for recurrence and those who may need further endocrine therapy.

Comments

In Channel

Noninvasive Biomarkers of AD Will Soon Be Reality

2018-03-2303:29

A New Prostate Cancer Screening Trial--Anything to See Here?

2018-03-1606:03

Overlooked Biomarker May Predict Cancer Immunotherapy Response

2018-02-1504:14

MABp1: 'Clever' New Antibody Targeting Colorectal Cancer

2018-02-1406:07

Next Steps for Immunotherapies, Cell Therapies in Oncology

2018-02-0923:22

'Cultural Change' in DCIS

2018-01-1712:32

Late Recurrence in ER- Positive Breast Cancer: Banking on Biomarkers

2018-01-1714:51

Wisely Choosing the Right Lab Tests

2017-12-1105:51

Gestational Diabetes and Long-term Risk for CVD

2017-11-0803:47

An Urgent Plea to Oncologists for HPV Vaccination

2017-11-0204:07

With Sudden Death, Don't Automatically Blame the Heart

2017-10-0911:56

Leading Science Journalist Carl Zimmer on His Genome

2017-10-0520:33

A Supplement That May Block The Toxic Effects of Alcohol

2017-09-2605:29

Life After the FDA: Mining Data and Reducing Disparities

2017-07-2014:44

'Sparks Fly' and 'Momentous Discovery' in Brain Diseases Follows

2017-07-0510:24

Antineoplastic Agents in Breast Cancers With Mutational Signatures

2017-04-1202:51

Biomarkers to Determine Who Gets Checkpoint Inhibitors

2017-04-0305:11

The Most Transformational Biologist of Our Era?

2017-03-3113:01

Is Precision Oncology Really Precise?

2017-03-1005:38

Are the Testosterone Trials the Final Word?

2017-03-0603:47

00:00

Late Recurrence in ER- Positive Breast Cancer: Banking on Biomarkers

#box-pro-ellipsis-176082366172770{-webkit-line-clamp:2;}Late Recurrence in ER- Positive Breast Cancer: Banking on Biomarkers

Late Recurrence in ER- Positive Breast Cancer: Banking on Biomarkers

Late Recurrence in ER- Positive Breast Cancer: Banking on Biomarkers